Pharmacogenomics Testing Market - Strategic Insights and Forecasts (2026-2031)

The Pharmacogenomics Testing market is expected to grow at a CAGR of 10.0%, rising to USD 17.9 billion in 2031 from USD 11.1 billion in 2026.

The pharmacogenomics testing market is expanding as healthcare shifts toward personalized medicine. Growing chronic disease prevalence, companion diagnostics development, and advancements in genomic technologies are driving demand. Despite cost and regulatory challenges, increasing digital integration and precision medicine initiatives are supporting long-term adoption across hospitals, research institutions, and specialty care settings globally.

Description

Pharmacogenomic testing helps clarify how drug response is changed by genetics. By identifying and quantifying these differences through pharmacogenomic testing, medication prescribing (selection of drugs and dosing) may be individualized for patients. The rapid expansion of this market results from changes occurring within healthcare systems which are transitioning from traditional medicine to precision medicine. These changes will help lower the occurrence of adverse drug reactions, provide better treatment outcomes, and enable more effective use of medication. Other contributing factors include increased awareness of clinical pharmacogenetics, enhanced use of genetic data in electronic health records, and strengthened collaboration between pharmaceutical and diagnostic industries to increase pharmacogenomics adoption among healthcare providers. The pharmacogenomics testing market consists of products (test kits, sequencing platforms, bioinformatics tools), laboratory services (used by hospitals, specialty clinics, and research institutions) and other services that will be used globally.

Pharmacogenomics Testing Market Analysis

Growth Drivers

·      Adoption of High-Throughput Sequencing Growth: The Illumina platforms for next-generation sequencing have been used extensively (e.g. by clinical laboratories) to conduct detailed pharmacogenomic profiling of many genes in one evaluation. The demand for the scalable Illumina sequencing systems continues to grow as clinical laboratories fully convert from using single gene tests to using high-­?thruput sequencing technologies.

·      Integration of Bioinformatics and Clinical Interpretation Tools: The bioinformatics and analytics workflows developed and supported by Illumina enable the interpretation of complex genetic data. This functionality is useful in allowing clinicians to apply pharmacogenomic information to prescribing decisions, thus increasing clinical adoption of pharmacogenomics.

·      Precision Medicine Initiatives and Regulatory Support: The most recent precision medicine initiatives are beginning to include pharmacogenomic testing in their drug prescribing guidelines. In terms of pharmacogenomics, Illumina's platforms are consistent with the aims of precision medicine initiatives by enabling genotype guided prescribing and creating a framework to incorporate pharmacogenomic testing into healthcare systems.

·      Partnerships with Healthcare and Pharma: The partnership opportunities created by Illumina with hospitals, research alliances, and pharmaceutical companies speed up the integration of pharmacogenomics into clinical trials and everyday practice by increasing the utilisation rates and profitability of Illumina's platforms.

Challenges and Opportunities

·      The market offers a lot of promise but continues to be challenged by inconsistency in the use of clinical guidelines in different regions, a lack of awareness about pharmacogenetics among healthcare providers, and differences between reimbursement policies. The complexity of assessing how various multi-gene interactions impact response to a given drug will continue. As such, there are barriers to complete integration of pharmacogenetic testing in electronic health records because of privacy concerns and the need for standardisation across reporting formats. Nevertheless, concurrent to market challenges, there are many opportunities for growth resulting from government-funded research programs, a wider body of clinical evidence supporting pharmacogenetics, and inclusion or recommendations for testing in key therapeutic guidelines. Additionally, there are some very promising trends in emerging markets (i.e., the growing demand for testing and drugs based on pharmacogenetics), advances in rapid point-of-care assays, and increasing collaboration between diagnostic and pharmaceutical manufacturers that will all contribute to market growth.

Key Development

·      October 2025: Illumina, Inc. officially launched its 5-Base solution, a novel sequencing platform that enables simultaneous detection of both genomic variants and DNA methylation from a single sample workflow. The solution uses proprietary 5-base chemistry and enhanced DRAGEN analysis to deliver high-resolution insights into both the methylome and genome, streamlining epigenetic and genetic analysis for research and clinical applications. This development improves efficiency and reduces costs for epigenetic diagnostics, particularly in oncology and rare disease biomarker discovery, and positions dual-omic testing as a scalable solution for clinical labs

Market Segmentation

The market is segmented by product type, technology, application and geography.

By Product Type: Reagents & Kits

Kits & reagents have historically been the backbone of the market and offer a wide variety of ‘ready to use’ assay kits for the following areas: DNA methylation, histone modification, and chromatin analysis. Laboratories utilise these kits & reagents because they minimise variability, reduce the time required to perform tests and standardise procedures across research and clinical environments. With the continued expansion of diagnostic laboratories into molecular and precision medicine testing, there is a continued increase in the demand for validated, high sensitivity kits & reagents, this is particularly true where reproducibility is paramount, such as in oncology-related diagnostic panels.

By Technology: NGS

NGS dominates technologically due to its ability to analyse multiple genes simultaneously with high accuracy. It supports comprehensive pharmacogenomic profiling and companion diagnostics development, making it highly preferred in oncology and complex disease management.

By Application: Oncology

Oncology remains the leading application area as targeted cancer therapies rely heavily on genetic profiling. Pharmacogenomic testing improves treatment precision, reduces adverse reactions, and enhances clinical outcomes, driving strong demand within cancer care settings.

Regional Analysis

North America Market Analysis

The North American market for pharmacogenomics testing is dominated by its existing precision medicine programs, significant expenditures in health care, and favorable regulatory policies. The U.S. utilises guidance from the U.S. Food and Drug Administration (FDA) and clinical guidelines from organisations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) to incorporate pharmacogenomic markers into prescription drug labels. The widespread utilisation of electronic health records and clinical decision support tools allows for seamless incorporation of genetic test results into clinical workflows. Most private commercial insurance payers and many government payers are beginning to add guidelines-based pharmacogenomic testing to their coverage strategies, especially for oncology and cardiovascular medications. The Canadian government also funds research and programs related to genomics through its national genomic strategies.

South America Market Analysis

South American countries, led by Brazil and Argentina, are integrating pharmacogenomic testing into academic and tertiary healthcare settings. Government support for public health genomics and partnerships with global research consortia enhance evidence generation. Infrastructure and reimbursement policies vary, but oncology and cardiovascular pharmacogenomics testing are gaining traction. Regional guidelines, clinician education, and standardized reporting systems are improving clinical adoption and patient access.

Europe Market Analysis

The European market for pharmacogenomics testing is supported by precision medicine initiatives organized through the European Medicines Agency (EMA) and national health systems in the UK, Germany and France. Clinical guidelines provide genotype-based recommendations for physicians, especially for patients receiving treatment for oncology and depression. Genetic data are stored securely in accord with the General Data Protection Regulation (GDPR) and can be used by responder. Each country has its own policy regarding the reimbursement of pharmacogenomic tests and some countries with centralized health systems will be advancing allowing coverage for tests that are based on validated gene-drug pairings. Collaborative projects associated with Horizon Europe provide support for cross-border collaboration, data harmonization and evidence generation leading to clinical adoption throughout Europe.

Middle East and Africa Market Analysis

The Middle East & Africa region is at an early adoption stage, but government investments in genomic research centers, healthcare modernization, and collaborations with international institutions are expanding capabilities. Countries such as the UAE, Saudi Arabia, and South Africa are developing frameworks for genomic testing and personalised therapy as part of broader precision medicine initiatives. Private healthcare providers and academic centers lead the implementation of pharmacogenomics testing, with growing interest in oncology and transplant medicine.

Asia Pacific Market Analysis

The Asia-Pacific region is witnessing tremendous growth due to the increased healthcare infrastructure, awareness and government focus on genomic medicine. Laboratories and hospitals in China and Japan are developing genomic programs and integrating precision medicine into their healthcare delivery systems. In addition, healthcare systems in South Korea and Australia are utilising pharmacogenomic markers in drug development for drugs with sufficient evidence for theory-based gene-drug pairings. Regulatory requirements for the validation of pharmacogenomic tests are evolving and developing quickly.

List of Companies

·      Roche Diagnostics

·      Thermo Fisher Scientific

·      QIAGEN

·      Illumina

·      Abbott Laboratories

·      Agilent Technologies

·      Danaher Corporation

·      Myriad Genetics

·      Invitae

·      Bio-Rad Laboratories

Roche Diagnostics

Within its product offerings, one can find real-time PCR systems, high-throughput testing solutions, and companion diagnostics used for oncological, infectious diseases, and genetic testing. Its diagnostic technology facilitates laboratory automation and collaboration through integration with laboratory information systems, allowing for optimal workflows and data management. Roche also manufactures multiplex assays to enable the simultaneous detection of various pathogens. Furthermore, Roche's continuous investments in new technologies, including next-generation sequencing and biomarker discovery, are helping to solidify its role in the field of precision medicine. The breadth of Roche's portfolio and its global reach establish it as one of the leading diagnostic companies, helping to make it an essential component of clinical and reference labs.

Thermo Fisher Scientific

Thermo Fisher's Applied Biosystems brand manufactures and sells products that relate to genetic analysis, infectious disease identification, and research purposes. Additionally, Thermo Fisher's platforms provide high-throughput workflows, allowing labs to increase their testing capacity. Thermo Fisher also offers package solutions for integrated service/support to help labs achieve optimal assay performance and compliance. Thermo Fisher is well-known for its strong commitment to research and development in order to support ongoing innovation in testing and laboratory automation, positioning it to be a critical partner for clinical and research labs globally.

Pharmacogenomics Testing Market Scope: